Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech?s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing for the company. The funding, a Series C round, was led by RTW Investments. [?]